Genetic variation in three candidate genes and nicotine dependence, withdrawal and smoking cessation in hospitalized patients.

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this phase 3 clinical trial publication.

This study evaluates the relationship of six polymorphisms found in the CHRNA3, DRD2 and COMT genes with nicotine dependence, the ability to quit smoking and the occurrence of withdrawal symptoms after short-term use of nicotine patch in hospitalized patients.

Who Took Part

According to the abstract, 233 participants were involved.

By PubMed's age tags, the people studied were teenagers, young adults, adults, middle-aged adults, older adults and people over 80, both men and women.

The study included 233 participants from a double-blind, placebo-controlled trial of nicotine patch substitution with a 6-month follow-up period.

Nicotine dependence was assessed by the Fagerström Test for Nicotine Dependence (FTND) questionnaire, withdrawal symptoms by the Minnesota Nicotine Withdrawal Scale questionnaire and smoking cessation by self-reported abstinence at 1 week, 1 month and 6 months after treatment.

How the Study Was Run

The researchers set it up as a double-blind and placebo-controlled study.

As a double-blind Therapeutic nicotine (patch, non-peptide) study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Therapeutic nicotine (patch, non-peptide), giving a reference point.

What Was Measured

Topics PubMed links to this paper include Catechol O-Methyltransferase, Hospitalization, Nicotine, Polymorphism, Genetic, Receptors, Dopamine D2, Receptors, Nicotinic and Smoking Cessation.

What This Means in Plain Language

The paper is a double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide) in 233 participants.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2010 (Pharmacogenomics), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.